Adeno-Associated Virus (AAV) Packaging Services Global Market Report 2026

The adeno-associated virus (AAV) packaging services market size has grown rapidly in recent years. It will grow from $1.48 billion in 2025 to $1.64 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rising gene therapy research activities, increasing funding for rare disease research, growth in preclinical and clinical trial pipelines, expansion of biotechnology startups, advancements in viral vector production technologies.

The adeno-associated virus (AAV) packaging services market size is expected to see rapid growth in the next few years. It will grow to $2.52 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing approvals of gene therapies, rising demand for commercial-scale GMP manufacturing, growing investments in precision medicine, expansion of cell and gene therapy pipelines, increasing strategic partnerships between biotech firms and cdmos. Major trends in the forecast period include increasing demand for high-titer and high-purity aav production, expansion of GMP-compliant clinical-grade aav packaging, growing focus on scalable large-scale manufacturing capabilities, rising adoption of advanced analytical and release testing services, increasing outsourcing of aav vector manufacturing to cdmos.

The increasing demand for gene therapy development is projected to drive the growth of the adeno-associated virus (AAV) packaging services market in the coming years. Gene therapy development involves creating treatments that modify or replace defective genes to address diseases. The demand for gene therapy development is rising due to the increasing prevalence of genetic and rare diseases, which is driving the need for advanced treatments that target the underlying genetic causes of these conditions. Adeno-associated virus (AAV) packaging services support gene therapy development by offering specialized viral vector production and purification services that ensure scalable, high-quality AAV supply for clinical research and therapeutic applications. For example, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, at the end of the first quarter of 2023, there were 247 gene therapies in Phase II, and this figure increased by 5% to reach 260 by the end of the second quarter. Therefore, the increasing demand for gene therapy development is fueling the growth of the adeno-associated virus (AAV) packaging services market.

Key companies operating in the adeno-associated virus (AAV) packaging services market are focusing on developing innovative solutions such as on-demand AAV viral vector packaging platforms to enhance flexibility, accelerate research timelines, and ensure consistent high-quality viral vector production. On-demand AAV viral vector packaging platforms are services that provide customized AAV production in specific serotypes with quality controls, helping researchers save time and obtain consistent, high-titer vectors for gene delivery applications. For example, in January 2025, Addgene Inc., a US-based nonprofit scientific organization, launched Packaged on Request, an innovative AAV packaging service. It allows scientists to choose from over 3,000 AAV plasmids in Addgene’s repository and request packaging in serotypes including AAV1, AAV2, AAV5, AAV8, and AAV Retrograde capsids. Each preparation undergoes comprehensive quality control procedures, including ddPCR titering, purity testing, sterility testing, and viral genome sequencing, ensuring research-grade standards consistent with in-stock viral preps. The service also streamlines legal approvals and technology transfer processes, reducing administrative burden while maintaining high titers suitable for diverse in vivo and in vitro applications.

In December 2023, Ajinomoto Co. Inc., a Japan-based food and biotechnology company, acquired Forge Biologics Holdings LLC for $0.54 billion (JPY 82.8 billion). Through this acquisition, Ajinomoto intended to combine its proprietary aminoscience platform with Forge Biologics’ gene therapy CDMO expertise to accelerate its expansion into advanced healthcare and gene therapy manufacturing sectors. Forge Biologics Holdings LLC is a US-based gene therapy contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) production as well as plasmid DNA manufacturing and packaging for clinical and commercial applications.

Major companies operating in the adeno-associated virus (AAV) packaging services market are Thermo Fisher Scientific Inc., AGC Biologics Inc., Lonza Group AG, Charles River Laboratories International Inc., Resilience Biotechnologies Inc., GenScript Biotech Corporation, Takara Bio Inc., OxB CDMO Inc., 3PBIOVIAN, VectorBuilder, Genezen Labs, Addgene Inc., PackGene Biotech Inc., Porton Advanced Solutions Ltd., Creative Biogene, Yposkesi SAS, AAVnerGene Inc., Virovek Inc., WuXi Advanced Therapies Co. Ltd., BioInnovatise Inc.

North America was the largest region in the adeno-associated virus (AAV) packaging services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated virus (AAV) packaging services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adeno-associated virus (AAV) packaging services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adeno-associated virus (AAV) packaging services market consists of revenues earned by entities by providing services such as vector design and cloning, plasmid construction, recombinant AAV production, viral packaging and amplification, purification, titration and quality control testing, and custom serotype selection. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adeno-associated virus (AAV) packaging services are specialized laboratory services that produce recombinant AAV vectors by inserting a target gene into AAV particles for research or therapeutic purposes. These services include plasmid design, vector assembly, viral production in suitable host cells, purification, and quality control testing to ensure high titer and purity. They allow efficient and stable gene delivery for research and therapeutic applications.

The significant service types of adeno-associated virus (AAV) packaging services include research-grade adeno-associated virus (AAV) packaging (RUO), good manufacturing practice (GMP) clinical AAV packaging, GMP late-stage and commercial supply, analytical and release testing, and process development and technology transfer. Research-grade AAV packaging (RUO) refers to services designed for laboratory research and preclinical studies. Vector types include AAV 2, AAV 5, AAV 8, and AAV 9 with production scales ranging from small-scale to mid-scale and large-scale. Therapeutic applications cover ophthalmology, neuromuscular and central nervous system disorders, metabolic or rare genetic disorders, oncology, cardiovascular, and others, serving end users such as biotechnology and biopharmaceutical firms, academic and research institutes, contract research organizations, contract manufacturing organizations, and healthcare and diagnostic laboratories.

Tariffs on imported bioprocessing equipment, plasmid raw materials, cell culture media, and laboratory consumables have impacted the AAV packaging services market by increasing operational and production costs, particularly affecting GMP clinical packaging and large-scale commercial supply segments. Regions such as North America, Europe, and Asia-Pacific that rely on cross-border supply chains for specialized biomanufacturing inputs are most affected. Analytical testing and process development services also face cost pressures due to imported reagents and instruments. However, tariffs are encouraging localized biomanufacturing infrastructure, domestic raw material production, and regional CDMO expansion, strengthening long-term supply chain resilience and reducing dependency on imports.

The adeno-associated virus (AAV) packaging services market research report is one of a series of new reports that provides adeno-associated virus (AAV) packaging services market statistics, including adeno-associated virus (AAV) packaging services industry global market size, regional shares, competitors with a adeno-associated virus (AAV) packaging services market share, detailed adeno-associated virus (AAV) packaging services market segments, market trends and opportunities, and any further data you may need to thrive in the adeno-associated virus (AAV) packaging services industry. This adeno-associated virus (AAV) packaging services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.